Literature DB >> 25920756

Computed Tomography--Verified Leukoaraiosis Is a Risk Factor for Post-thrombolytic Hemorrhage.

Lasse Willer1, Inger Havsteen2, Christian Ovesen1, Anders F Christensen3, Hanne Christensen1.   

Abstract

BACKGROUND: Is computed tomography (CT)-verified leukoaraiosis (LA) a risk factor for post-thrombolytic hemorrhagic transformation and symptomatic hemorrhage?
METHODS: (1) Retrospective analysis based on a prospectively planned single-center registry of consecutive tissue plasminogen activator (tPA)-treated patients within 4.5 hours from symptom onset. Standard work-up included baseline noncontrast CT and CT angiography and next day follow-up noncontrast CT. Baseline noncontrast CT LA was graded using Fazekas' score and dichotomized as the absence (Fazekas, 0) or the presence (Fazekas, 1-3). Hemorrhagic transformation was rated using European Cooperative Acute Stroke Study (ECASS) criteria. Symptomatic intracerebral hemorrhage was defined as hemorrhage and deterioration of National Institutes of Health Stroke Scale (NIHSS) of 4 or greater within 36 hours from symptom onset. Endovascularly treated patients were excluded. (2) Pooled analysis with 1312 tPA-treated patients from literature.
RESULTS: In all, 311 tPA-treated patients were included between April 2009 and July 2012. LA was present in 113 (36%). Twenty-three (7%) showed hemorrhagic transformation. LA positive patients had significantly higher hemorrhagic transformation frequency (11.5%, P = .04). LA doubled hemorrhagic transformation risk (odds ratio [OR], 2.4; 95% confidence interval [CI], 1.4-5.8). Only 4 patients developed symptomatic intracerebral hemorrhage, 3 with LA. LA was not an independent risk factor for hemorrhagic transformation (P = .2). Pooled analysis of 1623 patients in total, hereof 479 LA positive patients, showed significantly higher symptomatic intracerebral hemorrhage frequency in 35 (7.3%) LA positive than that in 44 (3.8%) LA negative patients, (P = .005) and doubled symptomatic intracerebral hemorrhage risk in LA positives (OR, 1.97; 95% CI 1.22-3.19).
CONCLUSIONS: LA doubles the risk of post-thrombolytic hemorrhagic transformation and symptomatic hemorrhage; this finding does not support withholding thrombolysis from patients with LA.
Copyright © 2015 National Stroke Association. Published by Elsevier Inc. All rights reserved.

Entities:  

Keywords:  Leukoaraiosis; brain hemorrhage; computed tomography; thrombolytic therapy

Mesh:

Substances:

Year:  2015        PMID: 25920756     DOI: 10.1016/j.jstrokecerebrovasdis.2014.12.018

Source DB:  PubMed          Journal:  J Stroke Cerebrovasc Dis        ISSN: 1052-3057            Impact factor:   2.136


  10 in total

1.  Stroke outcomes are worse with larger leukoaraiosis volumes.

Authors:  Wi-Sun Ryu; Sung-Ho Woo; Dawid Schellingerhout; Min Uk Jang; Kyoung-Jong Park; Keun-Sik Hong; Sang-Wuk Jeong; Jeong-Yong Na; Ki-Hyun Cho; Joon-Tae Kim; Beom Joon Kim; Moon-Ku Han; Jun Lee; Jae-Kwan Cha; Dae-Hyun Kim; Soo Joo Lee; Youngchai Ko; Yong-Jin Cho; Byung-Chul Lee; Kyung-Ho Yu; Mi Sun Oh; Jong-Moo Park; Kyusik Kang; Kyung Bok Lee; Tai Hwan Park; Juneyoung Lee; Heung-Kook Choi; Kiwon Lee; Hee-Joon Bae; Dong-Eog Kim
Journal:  Brain       Date:  2016-12-22       Impact factor: 13.501

2.  Severe cerebral hypovolemia on perfusion CT and lower body weight are associated with parenchymal haemorrhage after thrombolysis.

Authors:  S Tsetsou; M Amiguet; A Eskandari; R Meuli; P Maeder; B Jiang; M Wintermark; P Michel
Journal:  Neuroradiology       Date:  2016-12-27       Impact factor: 2.804

3.  Leukoaraiosis, Cerebral Hemorrhage, and Outcome After Intravenous Thrombolysis for Acute Ischemic Stroke: A Meta-Analysis (v1).

Authors:  Andreas Charidimou; Marco Pasi; Marco Fiorelli; Sara Shams; Rüdiger von Kummer; Leonardo Pantoni; Natalia Rost
Journal:  Stroke       Date:  2016-08-04       Impact factor: 7.914

Review 4.  Leukoaraiosis, intracerebral hemorrhage, and functional outcome after acute stroke thrombolysis.

Authors:  Kannikar Kongbunkiat; Duncan Wilson; Narongrit Kasemsap; Somsak Tiamkao; Fatima Jichi; Vanessa Palumbo; Michael D Hill; Alastair M Buchan; Simon Jung; Heinrich P Mattle; Nils Henninger; David J Werring
Journal:  Neurology       Date:  2017-01-27       Impact factor: 9.910

5.  Evaluation of eight-style Tai chi on cognitive function in patients with cognitive impairment of cerebral small vessel disease: study protocol for a randomised controlled trial.

Authors:  Xiaoyong Zhong; Xinghui Yan; Hui Liang; Rui Xia; Bin Chen; Hong-Jia Zhao
Journal:  BMJ Open       Date:  2021-02-08       Impact factor: 2.692

6.  Hypertension and Other Determinants of White Matter Lesions in Stroke Patients.

Authors:  Antonio Muscari; Luca Faccioli; Marco Ghinelli; Chiara Napoli; Enrico Pirazzoli; Giovanni M Puddu; Luca Spinardi; Marco Pastore Trossello; Marco Zoli
Journal:  J Clin Hypertens (Greenwich)       Date:  2016-01-28       Impact factor: 3.738

7.  Increased Risk of Post-Thrombolysis Intracranial Hemorrhage in Acute Ischemic Stroke Patients with Leukoaraiosis: A Meta-Analysis.

Authors:  Qianqian Lin; Zhong Li; Rui Wei; Qingfeng Lei; Yunyun Liu; Xiaodong Cai
Journal:  PLoS One       Date:  2016-04-20       Impact factor: 3.240

8.  Editorial: Imaging in Acute Stroke-New Options and State of the Art.

Authors:  Anders Fogh Christensen; Hanne Christensen
Journal:  Front Neurol       Date:  2018-01-11       Impact factor: 4.003

9.  Leukoaraiosis and risk of intracranial hemorrhage and outcome after stroke thrombolysis.

Authors:  Chun-Ming Yang; Chien-Ling Hung; Hui-Chen Su; Huey-Juan Lin; Chih-Hung Chen; Chou-Ching Lin; Han-Hwa Hu; Sheng-Hsiang Lin; Pi-Shan Sung
Journal:  PLoS One       Date:  2018-05-01       Impact factor: 3.240

10.  High Neutrophil-to-Lymphocyte Ratio Predicts Hemorrhagic Transformation in Acute Ischemic Stroke Patients Treated with Intravenous Thrombolysis.

Authors:  Yong-Lin Liu; Jie-Kai Lu; Han-Peng Yin; Pei-Shan Xia; Dong-Hai Qiu; Man-Qiu Liang; Jian-Feng Qu; Yang-Kun Chen
Journal:  Int J Hypertens       Date:  2020-02-27       Impact factor: 2.420

  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.